Biotech News
Related news
BLTEBelite Bio2026-07-15 12:00 EST
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
OKYOOKYO Pharma2026-07-21 13:00 EST
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
OKYOOKYO Pharma2026-09-08 11:00 EST
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
TARSTarsus Pharmaceuticals2026-11-05 21:30 EST
Tarsus to Participate in Upcoming Investor Conferences
OTLKOutlook2026-08-27 13:01 EST
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
OCSOculis2026-10-07 06:00 EST
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
SGHTSight Sciences2026-09-01 20:05 EST
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
OCSOculis2026-08-10 07:30 EST
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
RHHBYRoche Holdings AG2026-10-23 17:30 EST
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-11-03 21:05 EST
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
OCSOculis2026-11-02 07:00 EST
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
OCSOculis2026-10-29 09:39 EST
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
OCSOculis2026-10-22 06:00 EST
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
OCSOculis2026-10-20 06:00 EST
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Stock data
- Close
- 6.83 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States